All In Biotech

Drug Trial Radar · NCT04502862

A Phase 4, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Persistent Asthma

Last checked: Nov 20, 2026Latest source record: Dec 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 202 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

202

Actual

Start

Aug 10, 2020

Primary completion

Oct 3, 2023

Study completion Nov 10, 2023

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
Collaborators
Regeneron Pharmaceuticals
First posted
Aug 6, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: To assess the effect of dupilumab on sleep Secondary Objectives: * To evaluate the effect of dupilumab on additional participant reported sleep outcomes * To evaluate the effect of dupilumab on objective sleep assessment * To evaluate the effect of dupilumab on asthma symptoms * To evaluate the effect of dupilumab on lung function * To evaluate the safety of dupilumab

Conditions

  • Asthma

Interventions

  • SAR231893Drug

    Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous

  • PlaceboDrug

    Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to Week 12 in Sleep Disturbance Score Using the Asthma Sleep Disturbance Questionnaire (ASDQ)Time frame: Baseline (Day -6 to Day 1) up to Week 12

Locations

55 sites in 11 countries. Site status is shown where the registry gives one.

  • Kern Allergy and Medical Research. Inc. Site Number : 8400003

    Bakersfield, California

  • Todd Astor MD Site Number : 8400016

    Culver City, California

  • Southern California Institute for Respiratory Diseases Site Number : 8400009

    Los Angeles, California

  • Allergy & Asthma Associates of Santa Clara Valley Site Number : 8400001

    San Jose, California

  • Asthma and Allergy Associates, PC Site Number : 8400011

    Colorado Springs, Colorado

  • Sarasota Clinical Research Site Number : 8400012

    Sarasota, Florida

  • Allergy & Asthma Specialists, PSC Site Number : 8400004

    Owensboro, Kentucky

  • The Asthma and Allergy Center Site Number : 8400010

    Bellevue, Nebraska

  • OK Clinical Research LLC Site Number : 8400005

    Edmond, Oklahoma

  • Velocity Clinical Research, Medford Site Number : 8400007

    Medford, Oregon

  • National Allergy and Asthma Research, LLC Site Number : 8400008

    Charleston, South Carolina

  • TTS Research Site Number : 8400006

    Boerne, Texas

  • Investigational Site Number : 0320002

    Buenos Aires, Argentina

  • Investigational Site Number : 0320003

    CABA, Buenos Aires, Argentina

  • Investigational Site Number : 0320001

    CABA, Buenos Aires, Argentina

  • Investigational Site Number : 0320004

    Rosario, Santa Fe Province, Argentina

  • Investigational Site Number : 0320005

    Rosario, Santa Fe Province, Argentina

  • Investigational Site Number : 1240009

    Québec, Canada

  • Investigational Site Number : 1240008

    Windsor, Canada

  • Investigational Site Number : 1240012

    Ajax, Ontario, Canada

  • Investigational Site Number : 1240005

    Toronto, Ontario, Canada

  • Investigational Site Number : 2760002

    Berlin, Germany

  • Investigational Site Number : 2760005

    Frankfurt am Main, Germany

  • Investigational Site Number : 2760003

    Hanover, Germany

  • Investigational Site Number : 2760001

    Koblenz, Germany

  • Investigational Site Number : 2760004

    Leipzig, Germany

  • Investigational Site Number : 2760006

    Lübeck, Germany

  • Investigational Site Number : 3800005

    Reggio Emilia, Italy

  • Investigational Site Number : 3800006

    Monserrato, Cagliari, Italy

  • Investigational Site Number : 3800001

    Orbassano, Torino, Italy

  • Investigational Site Number : 5280005

    Arnhem, Netherlands

  • Investigational Site Number : 5280001

    Breda, Netherlands

  • Investigational Site Number : 5280002

    Leeuwarden, Netherlands

  • Investigational Site Number : 6200001

    Aveiro, Portugal

  • Investigational Site Number : 6200007

    Guimarães, Portugal

  • Investigational Site Number : 6200006

    Lisbon, Portugal

  • Investigational Site Number : 6200003

    Matosinhos Municipality, Portugal

  • Investigational Site Number : 6200004

    Porto, Portugal

  • Investigational Site Number : 6430001

    Moscow, Russia

  • Investigational Site Number : 6430002

    Moscow, Russia

Showing 40 of 55 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.